Fig. 9
From: Advances in molecular pathology and therapy of non-small cell lung cancer
Recommended therapy algorithm for non-oncogene addicted metastatic NSCLC. This flowchart categorizes immunotherapy options primarily based on the characteristics of the drugs and the features of the tumor, which are currently numerous and should be selected based on availability. While standard regimens exist for chemotherapy combined with immunotherapy, special considerations, such as the neurotoxicity associated with nab-paclitaxel, may necessitate alternative treatment strategies. Anti-angiogenic biosimilars can serve as parallel substitutes
